| Business Summary | | MacroChem
Corporation
develops
pharmaceutical
products
for
commercialization
by
applying
SEPA
(Soft
Enhancer
of
Percutaneous
Absorption),
its
patented
topical
drug
delivery
technology.
SEPA
compounds,
when
properly
combined
with
drugs,
provide
pharmaceutical
formulations
(such
as
creams,
gels
and
solutions)
that
enhance
the
transdermal
delivery
of
drugs
into
the
skin
or
into
the
bloodstream.
SEPA
compounds
are
designed
to
enhance
the
diffusion
of
drugs
into
and
through
the
skin
by
making
the
outer
layer
of
the
skin
more
permeable
to
the
drug
molecule. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | MacroChem
Corp.
engages
in
the
development
and
commercialization
of
transdermal
drug
delivery
compounds
and
systems
designed
to
promote
the
delivery
of
drugs
from
the
surface
of
the
skin
into
the
skin
and
bloodstream.
For
the
six
months
ended
6/30/01,
revenues
fell
from
$572
thousand
to
$0.
Net
loss
increased
22%
to
$6.6
million.
Results
reflect
the
termination
by
AHP
of
the
Co.'s
license
agreement
and
increased
research
and
development
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| John Zabriskie, Ph.D., 61 Chairman | -- | Robert Palmisano Pres,
CEO | -- | Bernard Patriacca CFO,
VP | -- | Kenneth Rice, Jr., 47 VP,
Treasurer, Sec. | $170K | Paul Schechter, M.D., Ph.D., 61 VP,
Drug Devel. & Regulatory Affairs | 209K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|